Regulation of H2S signaling in vascular function
Regulation of H2S signaling in vascular function
批准号:
10701780
负责人:
Jay S Naik
金额:
$52.42万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-10 至 2026-06-30
关键词:
ArteriesBindingBiologyBlood VesselsBlood flowCalciumCarbon MonoxideCardiovascular DiseasesCardiovascular systemCell membraneCell physiologyCholesterolCirculationComplexDataDiseaseDisparateEndothelial CellsEndotheliumEventFamilyFunctional disorderGene ExpressionGoalsHemeHomeostasisHydrogen SulfideHypertensionImpairmentIn VitroKnowledgeLeftMediatingMembraneMembrane LipidsMesenteric ArteriesMesenteryNitric OxideOrganOxygenasesPathway interactionsPeripheral Vascular DiseasesPhospholipid Transfer ProteinsPotassium ChannelPrincipal InvestigatorProductionPropertyProteinsRegulationReportingResistanceRoleSignal TransductionSignaling MoleculeSiteStrokeSystemTestingTherapeuticTherapeutic InterventionVanilloidVascular Endothelial CellVasodilationVasodilator AgentsWorkblood pressure regulationcholesterol controlcholesterol traffickinggenetic approachin vivoinnovationmeternew therapeutic targetnovelpharmacologicprogramsreceptorregional differencerepairedresponsesingle-cell RNA sequencingtargeted treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Program Director/Principal Investigator (Last, First, Middle): Naik, Jay, S
Impaired endothelial cell (EC) function is one of the first indicators of systemic cardiovascular disease. EC
dysfunction impairs local organ blood flow regulation, a primary cause of end-organ damage in most
cardiovascular diseases. The discovery that ECs also synthesize carbon monoxide (CO) and hydrogen sulfide
(H2S), in addition to nitric oxide (NO), which elicits vasodilation has opened a new chapter in endothelial
gasotransmitter biology. While increasing evidence supports a key role for H2S in cardiovascular homeostasis,
disparate findings in previous studies leaves a significant gap in knowledge on the regulation and significance of
H2S signaling in the vasculature. Recently, we identified a novel regulator of H2S signaling that leads to profound
differences in vasodilatory sensitivity between primary and tertiary segments of the circulation. Intriguingly, our
preliminary data show that H2S dilates small (resistance) arteries in an endothelium-dependent manner at
concentrations that have no effect in large arteries. However, depleting EC membrane cholesterol in large
arteries unmasks H2S-mediated vasodilation, suggesting membrane lipid content and domains regulate H2S
signaling. Moreover, our preliminary data show that native EC cholesterol content is greater in large arteries than
resistance arteries. The concept that innate regional differences in EC membrane cholesterol content mediate
functional differences in EC dilation is wholly novel, and our preliminary data (Fig. 6) demonstrate this may be
caused by increased cholesterol efflux via ATP-binding cassette family a1 (Abca1) and phospholipid transfer
protein (Pltp). Importantly, we have previously shown that changes in EC membrane cholesterol appear to
contribute to dysfunction in disease. Therefore, EC membrane cholesterol is an important but uninvestigated
variable in vascular function. The overall goal of this project is two-fold. First, to elucidate mechanisms leading
to the functionally significant differences we have observed in EC membrane cholesterol content between large
and small arteries. The second is to define ways in vitro and in vivo that these differences in EC membrane
cholesterol control EC function, specifically H2S-induced dilation. Thus, we hypothesize that augmented
cholesterol efflux in EC of resistance arteries enhances downstream H2S signaling
Aim 1: Determine the mechanism(s) leading to heterogeneous membrane cholesterol content between
large and small arteries.
Aim 2: Determine the mechanism(s) by which membrane cholesterol regulates H2S signaling in EC.
Completing the proposed studies will fill an existing knowledge gap by elucidating the regulation of H2S dilation
to identify differences in EC function between small and large arteries. Conceptually, the project is very innovative
in its focus on the novel ability of membrane cholesterol trafficking to act as a regulator of vasodilation. This work
will increase our understanding of the fundamental properties of EC, significantly impacting our understanding
of blood pressure regulation and local blood flow control, and may identify drug targets for the treatment of
multiple vascular-driven diseases.
OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page Continuation Format Page
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of H2S signaling in vascular function
-
批准号:10517850
-
项目类别:
-
资助金额:$53.76万
-
财政年份:2022
-
负责人:Jay S Naik
-
依托单位:
Functional hyperemia during metabolic syndrome
-
批准号:6994569
-
项目类别:
-
资助金额:$4.06万
-
财政年份:2005
-
负责人:Jay S Naik
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: